Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: Update Bulletin [December 2016]

Product Code:
596200708
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in the colorectal cancer (CRC) market: the release of data from the Phase III LUME-Colon 1 trial of Boehringer Ingelheim’s nintedanib in pre-treated patients with metastatic colorectal cancer (mCRC); Amgen’s presentation of retrospective analyses of the PEAK and PRIME trials of Vectibix (panitumumab) at the European Society for Medical Oncology (ESMO) 2016 Congress; the initiation of the Phase III CanStem303C trial of Boston Biomedical’s napabucasin (BBI-608).

Business Questions:

  • How do KOLs view the data from the Phase III LUME-Colon 1 trial of Boehringer Ingelheim’s nintedanib?
  • How can the lack of OS benefit in the Phase III LUME-Colon 1 trial be explained?
  • If nintedanib were to be approved for the treatment of CRC, how widely would it be used?
  • How do KOLs view the tolerability profile of nintedanib?
  • How do KOLs interpret the recently presented retrospective analyses of the PEAK and PRIME trials of Vectibix?
  • Which settings do KOLs regard as the most effective for the use of Vectibix and how has its use recently changed?
  • How do KOLs view the overall potential for Boston Biomedical’s napabucasin to be a safe and effective therapy for mCRC?
  • How do KOLs view the design of the Phase III CanStem303C trial of napabucasin?
  • Where in the CRC treatment algorithm is napabucasin likely to be most effective?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved